Hyloris Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Stijn Van Rompay
Chief executive officer
€212.8k
Total compensation
| CEO salary percentage | 89.7% |
| CEO tenure | 4.8yrs |
| CEO ownership | 36.7% |
| Management average tenure | no data |
| Board average tenure | 4.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €213k | €191k | -€15m |
Compensation vs Market: Stijn's total compensation ($USD232.06K) is below average for companies of similar size in the Belgian market ($USD707.51K).
Compensation vs Earnings: Insufficient data to compare Stijn's compensation with company performance.
CEO
Stijn Van Rompay (48 yo)
4.8yrs
Tenure
€212,820
Compensation
Mr. Stijn Van Rompay is a Co-Founder and Chief Executive Officer of Hyloris Pharmaceuticals SA and serves as its Director since 2020. He was the Chief Executive Officer of Alter Pharma, a high-growth pharm...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.8yrs | €212.82k | 36.67% € 62.2m | |
| Co-Founder | 4.8yrs | no data | 13.78% € 23.4m | |
| Independent Director | 4.8yrs | €17.50k | no data | |
| Chairman of the Board | 4.8yrs | €22.50k | no data | |
| Non-Executive Director | 4.8yrs | €12.50k | no data | |
| Independent Director | 3.3yrs | €17.50k | no data | |
| Non-Executive Director | 4.8yrs | €17.50k | no data | |
| Independent Director | 4.8yrs | €22.50k | no data |
4.8yrs
Average Tenure
61yo
Average Age
Experienced Board: HYL's board of directors are considered experienced (4.8 years average tenure).